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Background: It is not known if there is a differential impact on Alzheimer’s disease (AD) diagnosis and outcomes
if/when patients are diagnosed with cognitive decline by specialists versus non-specialists. This study examined the
cost trajectories of Medicare beneficiaries initially diagnosed by specialists compared to similar patients who
received their diagnosis in primary care settings.
Methods: Patients with ≥2 claims for AD were selected from de-identified administrative claims data for US Medicare
beneficiaries (5 % random sample). The earliest observed diagnosis of cognitive decline served as the index date.
Patients were required to have continuous Medicare coverage for ≥12 months pre-index (baseline) and ≥12 months
following the first AD diagnosis, allowing for up to 3 years from index to AD diagnosis. Time from index date to AD
diagnosis was compared between those diagnosed by specialists (i.e., neurologist, psychiatrist, or geriatrician) versus
non-specialists using Kaplan-Meier analyses with log-rank tests. Patient demographics, Charlson Comorbidity Index
(CCI) during baseline, and annual all-cause medical costs (reimbursed by Medicare) in baseline and follow-up periods
were compared across propensity-score matched cohorts.
Results: Patients first diagnosed with cognitive decline by specialists (n = 2593) were younger (78.8 versus 80.8 years
old), more likely to be male (40 % versus 34 %), and had higher CCI scores and higher medical costs at baseline than
those diagnosed by non-specialists (n = 13,961). However, patients diagnosed by specialists had a significantly shorter
time to AD diagnosis, both before and after matching (mean [after matching]: 3.5 versus 4.6 months, p < 0.0001). In
addition, patients diagnosed by specialists had significantly lower average total all-cause medical costs in the first
12 months after their index date, a finding that persisted after matching ($19,824 versus $25,863, p < 0.0001). Total
per-patient annual medical costs were similar for the two groups starting in the second year post-index.
Conclusions: Before and after matching, patients diagnosed by a specialist had a shorter time to AD diagnosis and
incurred lower costs in the year following the initial cognitive decline diagnosis. Differences in costs converged during
subsequent years. This suggests that seeking care from specialists may yield more timely diagnosis, appropriate care
and reduced costs among those with cognitive decline.
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Alzheimer’s disease (AD) is a progressive neurodegener-
ative disease and the most common form of dementia in
those over the age of 65 [1]. Approximately 5.3 million
Americans have AD and this number is projected to be
13.8 million by 2050 [2].
Total payments in 2015 for healthcare, long-term care,
and hospice care for Americans aged 65 years and older
with dementia were estimated to be $226 billion [2]. In
addition, it is estimated that more than 15.7 million fam-
ily members and other unpaid caregivers provided an es-
timated 17.9 billion hours of care to people with AD and
other dementias, a contribution valued at $217.7 billion
in 2014 [2]. Further research suggests that the healthcare
system may be paying for additional direct medical costs
incurred by spouses and household members of persons
with AD [3, 4].
Given that AD is an age-related disease and that most
dementia cases are for persons over the age of 65, Medi-
care has been, and will remain, the main funding source
for medical treatment of patients with AD. However,
recent legislation [5] acknowledges that the current
healthcare system is not designed to address the com-
plexities of care management for AD patients. Further-
more, dementia-related quality measures are not yet an
integral part of the current healthcare system [6] and
there is a need to identify ways to improve the diagnosis
and outcomes for AD patients.
An accurate and timely initial dementia diagnosis may
help patients and caregivers better plan for managing
the underlying disease and may lower costs to healthcare
systems [7, 8]. However, detection and diagnosis of
dementia can be challenging because of the complex
presentation of symptoms, many of which overlap with
manifestations of other conditions [9]. Literature has
shown that this is particularly problematic in the pri-
mary care setting. For example, in a study by Borson
et al. [10], primary care physicians correctly identified
only 41 % of cognitively impaired patients. A meta-
analysis of detection, diagnosis, and documentation rates
in the existing primary care environment suggests highly
variable detection rates for the presence of cognitive im-
pairment. Diagnosis rates are generally higher in more
severe stages, but documentation rates for dementia and
cognitive impairment remain low [11].
Though the constraints of primary care practice re-
lated to dementia diagnosis have been examined, it is
not known if there is a differential impact on AD diag-
nosis and outcomes if/when specialists are included in
care. For example, given the complexities of diagnosis
and management, diagnosis of AD by specialists, who
have additional training and expertise in this area, may
be preferable. However, this approach could increase
costs of care and create additional hurdles in thehealthcare system due to the low number of available
specialists. For example, Dall et al. [12] estimate a 19 %
shortfall of neurologists by 2025. It is therefore import-
ant to better understand the links between care setting
at the time of dementia diagnosis and subsequent out-
comes (e.g., healthcare resource use and costs).
The current study looks to inform the literature by
examining the cost trajectories of Medicare beneficiaries
initially diagnosed with cognitive decline by specialists
compared to similar Medicare recipients who received
their diagnosis in primary care settings. If differences
exist, the type of difference may be informative for dis-




This study used data from the Medicare Standard Ana-
lytical files containing de-identified administrative claims
for a 5 % random sample of fee-for-service Medicare
beneficiaries (~3-million). Prior to 2009, these data did
not have precise dates of service available. Having a pre-
cise date of service was necessary to characterize key
outcomes of our study (e.g. time to AD diagnosis). This
analysis, therefore, used the most recent years available
(2009 through 2012) to identify patients diagnosed with
cognitive decline. The data include patient demographics
(age and gender), enrollment history, medical diagnoses
received and associated dates of service, place of service
(e.g., hospitalizations, physician office visits, emergency
department (ED) visits), provider specialty, and paid
amounts. Prescription drug claims were not available.
Sample selection
Medicare beneficiaries with at least two distinct claims
with a diagnosis code for Alzheimer’s disease (Inter-
national Classification of Diseases, Ninth Revision, Clin-
ical Modification [ICD-9-CM] code 331.0), with the first
such claim occurring in the period 2009 through 2012,
were identified as AD patients. The AD patients identified
in this same period (2009 through 2012) whose first claim
for cognitive impairment (“index date”; ICD-9-CM: 290.x,
291.1, 291.2, 292.82–83, 294.x, 331.x, 780.93) was before
or at the date of AD diagnosis were also included in the
analysis. Continuous Medicare enrollment was required
during the 12 months prior to the index date (baseline
period), the period between the index date and the first
AD diagnosis, and the 12 months following and including
the first AD diagnosis, resulting in a follow-up period of at
least 12 months and up to 36 months after the index date
(Fig. 1). Patients were then stratified into two cohorts de-
pending on whether they were first diagnosed as having
cognitive impairment (i.e., on their index date) by a spe-
cialist or not. A diagnosis was considered to be made by a
Fig. 1 Study time periods
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specialty as a neurologist, psychiatrist, or geriatrician.
Propensity score matching
AD patients diagnosed with cognitive impairment by a
specialist were matched one-to-one by greedy matching
algorithm to patients diagnosed in a primary care setting
using propensity scores [13], length of follow-up, and
medical costs in the baseline period (±1/10 of the aver-
age baseline costs among patients diagnosed by a spe-
cialist). Propensity scores (i.e., likelihood of being
diagnosed by a specialist) were estimated using a logistic
regression model that accounted for differences in base-
line characteristics across the two cohorts, including
patient-level demographics (age, gender, and year of
index date), Charlson Comorbidity Index (CCI) [14],
hyperlipidemia, and depression.
Outcomes
Time to AD diagnosis, defined as time from the index
date (i.e., earliest observed indication of cognitive
decline) to AD diagnosis, was compared between the pa-
tients diagnosed by a specialist and those diagnosed by
non-specialists. All-cause medical costs from the payer
perspective (i.e., payments by Medicare to providers in
2012 US dollars) were evaluated in each year of follow-
up among matched pairs of patients with continuous
Medicare eligibility for the duration of the entire year
being evaluated. Costs were further categorized by place
of service in order to identify the main sources of differ-
ences in medical costs. Categories of service included:
hospital inpatient, hospital outpatient, physician office,
home health, ED, skilled nursing facilities, durable med-
ical equipment, and hospice. Since prescription drug
claims were not available, drug costs were not included
in the analysis.
Statistical analyses
For categorical variables in baseline and follow-up, statis-
tical significance of differences between patients treated
by a specialist and controls was assessed using chi-squared tests prior to matching and McNemar tests after
matching. For continuous variables, statistical significance
was evaluated using Wilcoxon rank-sum tests prior to
matching and Wilcoxon signed-rank tests after matching.
Kaplan-Meier survival analysis was used for time to AD
diagnosis comparison between the patients diagnosed by a
specialist and those diagnosed by non-specialists. Statis-
tical analyses were performed using SAS version 9.3 (SAS
Institute Inc., Cary, NC). A p-value of < .05 was considered
as statistically significant.
Results
The selection criteria resulted in a final analytic sample
of 16,554 patients, of whom 2593 (15.7 %) were diag-
nosed by a specialist and 13,961 (84.3 %) were diagnosed
by non-specialists.
Time to AD diagnosis
Patients who received their first cognitive impairment
diagnosis by a specialist had a statistically significantly
shorter time to AD diagnosis (median 0.1, mean
3.6 months) compared to patients diagnosed by non-
specialists (median 1.2, mean 4.9 months) (Fig. 2). Re-
sults were similar after propensity score matching
(Table 1). Of note, 50 % of those diagnosed by specialists
received an AD diagnosis on their index date, compared
to 40 % of those diagnosed by non-specialists.
Baseline characteristics
Prior to matching, AD patients first diagnosed with
cognitive impairment by a specialist were younger (78.8
versus 80.8 years, p < 0.0001) and more likely to be male
(40 % versus 34 %, p < 0.0001) compared to those diag-
nosed by non-specialists. Additionally, patients diag-
nosed by specialists had significantly higher rates of
comorbidities such as hyperlipidemia (62 % versus 52 %,
p < 0.0001), stroke/cerebrovascular disease (28 % versus
20 %, p < 0.0001), and cardiovascular conditions includ-
ing hypertension and ischemic heart disease (Table 1).
Furthermore, those diagnosed by specialists had higher
total all-cause medical costs at baseline ($15,058 versus
Fig. 2 Time from index date to AD diagnosis date. NOTE: patients diagnosed by specialists versus no specialists (before matching)
Table 1 Patient characteristics during the 12 months prior to the index date










Age on index date, mean (SD) 78.8 (8.7) 80.8 (8.2) <0.0001 79.1 (8.3) 79.3 (8.1) 0.3593
% male 40 % 34 % <0.0001 40 % 39 % 0.4781
Charlson Comorbidity Index, mean (SD) 2.2 (2.2) 1.9 (2.1) <0.0001 2.1 (2.1) 2.1 (2.1) 0.5307
Comorbidities, %
Chronic obstructive pulmonary disease 18 % 17 % 0.8061 17 % 18 % 0.2465
Depression 20 % 18 % 0.0890 19 % 20 % 0.4097
Diabetes 31 % 29 % 0.1159 30 % 33 % 0.0123
Epilepsy 4 % 2 % <0.0001 3 % 2 % 0.0080
Hyperlipidemia 62 % 52 % <0.0001 61 % 63 % 0.1431
Hypertension 78 % 76 % 0.0270 77 % 80 % 0.0059
Ischemic heart disease 37 % 31 % <0.0001 36 % 35 % 0.1537
Other cardiovascular conditions 60 % 55 % <0.0001 59 % 58 % 0.4371
Stroke/cerebrovascular disease 28 % 20 % <0.0001 27 % 20 % <0.0001
Urinary tract infection 22 % 21 % 0.7036 21 % 23 % 0.0579
Time to AD diagnosis, mean (SD) 3.6 (6.2) 4.9 (7.2) <0.0001 3.5 (6.2) 4.6 (6.8) <0.0001
Months of follow-up, mean (SD) 29.8 (9.8) 31.2 (10.2) <0.0001 29.9 (9.8) 30.1 (10.0) 0.0105
Total healthcare costs, mean (SD)a $15,058 ($26,139) $13,339 ($24,356) <0.0001 $12,497 ($18,789) $12,503 ($18,797) 0.5597
*Calculated using Wilcoxon-rank sum tests for continuous variables and chi-square tests for categorical variables
**Calculated using Wilcoxon signed-rank tests for continuous variables and McNemar’s tests for categorical variables
aDollar values were inflated to 2012 US dollars using the medical care component of the Consumer Price Index
Note: Patients were one-to-one matched based on patients’ age, gender, year of index date, Charlson Comorbidity Index, hyperlipidemia, and depression by
propensity scores greedy method
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months of follow-up time available compared to those
diagnosed by non-specialists (Table 1).
The matching process resulted in identification of
2503 matched pairs of AD patients who were initially
diagnosed with cognitive impairment by a specialist and
AD patients diagnosed by non-specialists. The matched
cohorts had similar demographic characteristics and
baseline healthcare costs. However, those diagnosed by
specialists had higher rates of epilepsy and stroke, but
lower rates of diabetes and hypertension at baseline
compared with their matched counterparts (Table 1).
Costs during the follow-up period
Before matching, patients first diagnosed with cognitive
impairment by a specialist had significantly lower average
total all-cause medical costs in the first 12 months after their
index date ($20,809 versus $25,821, p < 0.0001; Fig. 3). This
cost differential persisted even after accounting for under-
lying differences using propensity score matching ($19,824
versus $25,863, p < 0.0001; Fig. 4). In the second and third
years of follow-up, the two cohorts had statistically similar
costs, both before and after matching (Figs. 3 and 4).
In terms of costs by place of service during the first
year of the follow-up period, AD patients first diagnosed
with cognitive impairment by a specialist had signifi-
cantly lower costs, on average, in every place of service
compared to the matched control population, with the
exception of physician office visits (Fig. 5). The differ-
ence in inpatient costs (−$2940, p < 0.0001) comprised
48.7 % of the difference in total medical costs among the
two cohorts, followed by the difference in skilled nursing
facility costs, which accounted for 32.9 % (−$1986, p <
0.0001) of the overall all-cause medical cost differential.Fig. 3 Average total all-cause costs in follow-up period. NOTE: patients diaDiscussion
Consulting a specialist upon first indications of cognitive
decline appears to be associated with a modestly shorter
time until diagnosis of AD. The shorter time to diagno-
sis is primarily because patients seen by a specialist are
more likely to receive an AD diagnosis on the index date
as opposed to a general diagnosis of cognitive impair-
ment prior to a more definitive diagnosis of AD. This
may be attributable to the fact that specialists have more
expertise in identifying dementia symptoms and there-
fore may be more comfortable making a diagnosis.
An alternative explanation could be related to the dif-
ferential rates of various comorbidities across the two
cohorts. For example, after matching, patients first diag-
nosed by specialists had significantly higher rates of epi-
lepsy and stroke/cerebrovascular disease, but patients
who were not first diagnosed by specialists had signifi-
cantly higher rates of diabetes and hypertension. Condi-
tions like epilepsy and stroke are likely already managed
by a specialist, so patients and their caregivers may be
more likely to self-refer to a specialist if additional or
worsening cognitive symptoms occur, thus resulting in a
faster diagnosis. Primary care physicians may also more
readily refer patients with a history of a major neuro-
logical disorder to a specialist. On the other hand, pri-
mary care providers may view symptoms of cognitive
decline in patients with diabetes and hypertension as
part of those chronic diseases and thus feel that an add-
itional diagnosis is not warranted or may take more time
to confirm that the cognitive deficit is significant enough
to merit a separate evaluation, focusing instead on more
controlled management of diabetes and hypertension.
However, recent work by Barnes et al. [15] suggests that
a history of type II diabetes should be part of thegnosed by specialists versus no specialists (before matching)
Fig. 4 Average total all-cause costs in follow-up period. NOTE: patients diagnosed by specialists versus no specialists (after matching)
Kirson et al. BMC Geriatrics  (2016) 16:138 Page 6 of 8primary care algorithm for identifying patients at high
risk for cognitive impairment. Broader dissemination of
these types of criteria and increased awareness by primary
care providers about risk factors for AD and other demen-
tias may help shorten the diagnostic process. It is also
worth considering that different types of patients may
present to primary care physicians versus specialists.
Prior to matching, patients diagnosed by specialists
had higher CCI scores and costs at baseline, despite
being younger. This would suggest that more complex
patients are seen by specialists. The expectation might
therefore be for higher costs to accrue after diagnosis asFig. 5 Components of costs in Year 1 of follow-up period. NOTE: patients dia
DME = durable medical equipment; SNF = skilled nursing facilities; USD = Unit
significant at p<0.05 for all places of service. Inpatient stays include stays origiwell. On the contrary, the present analyses suggest that
patients diagnosed by a specialist have lower costs in the
year following initial diagnosis. This pattern holds even
after matching on baseline characteristics including
demographics and all-cause medical costs.
In keeping with the National Alzheimer’s Project Act
goal of earlier diagnosis of AD, these results suggest that
seeking timely care from specialists may result in a
quicker diagnosis and reduced overall medical costs
among those with cognitive decline. These trends should
be monitored in the coming years as more patients make
use of benefits provided under the Affordable Care Act,gnosed by specialists versus no specialists (after matching). Abbreviations
ed States dollars. Note: Differences across cohorts are statistically
nating from the emergency department
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includes detection of any cognitive impairment among
eligible individuals (i.e., those who have had Medicare
Part B for longer than 12 months). The results of this
study suggest potential advantages of a specialist per-
forming the exam for certain individuals at risk for AD.
However, given the complexity of the disease and its
presentation, the best use of resources may be for simple
detection in the primary care setting followed by timely
referral to a specialist. An expected shortage in the avail-
ability of specialists makes it unlikely that more timely
receipt of an accurate diagnosis will be achieved without
initiatives that also focus on improving the diagnosis of
AD by primary care physicians. This may become even
more important in the future, as evidence is accumulat-
ing that the biggest potential for delaying progression
and/or modifying the disease trajectory appears to be
when intervening earlier in the disease continuum [17].
Although the present study provides some preliminary
data on possible benefits of specialist care for diagnosis,
limitations of claims data prohibit definitive statements
about which care setting is optimal. These analyses rely
on the accuracy of the ICD-9 coding of diagnoses in ad-
ministrative claims data, which do not necessarily reflect
confirmed clinical diagnoses and lack information to as-
sess the severity of illness. A recent report noted that
fewer than 50 % of individuals with AD reported being
told of their diagnosis [2]. To the extent a similar pat-
tern of under-reporting of AD diagnoses exists in billing
claims, this analysis does not characterize the full cohort
of AD patients in Medicare. It is unclear to what extent
the omission of these patients from our analysis may im-
pact our results. If the omitted AD patients are earlier in
the spectrum of disease, they may be less likely to be
seen by specialists and also cost less, thereby lowering
the average cost of the ‘No specialist’ cohort. In addition,
having detail on the severity of AD (e.g. Mild, Moderate
or Severe) would provide useful insights as to whether
the lower Year 1 costs among those treated by specialists
hold across all severity levels or whether the aggregate
difference is driven by a particular severity cohort. Re-
gardless of the completeness of the AD cohort and the
lack of specificity on severity, these results do describe
the cost trends stratified by type of treating physician at
the time of diagnosis of cognitive decline among individ-
uals eventually coded as having AD in Medicare claims.
Further research using data sources that allow more
complete and accurate identification of AD patients, in-
cluding by dementia severity, would be a valuable
addition to knowledge in this area.
The severity of symptoms at the time of diagnosis is
not known and may impact how well a patient is man-
aged in primary versus specialty care. The level and
quality of coordination between the primary careprovider and specialist is also not known. For example,
lower costs of care in patients seen by specialists may be
due to efforts of proactive primary care providers,
caregivers, and patients who reach out more quickly
to specialists and take a more active care manage-
ment and coordination role. In addition, costs do not
reflect prescription drug use, medical services covered
by other payers (e.g., Medicare/Medicaid dual eligibil-
ity), or over-the-counter medications or informal care.
Additionally, while the propensity score matching ana-
lysis controlled for observable differences across patient
cohorts, it cannot account for unobserved heterogeneity.
Furthermore, in addition to a more timely diagnosis,
treatment by a specialist may also result in a more de-
tailed, tailored treatment plan that allows for better pa-
tient management and thus lowers costs. However, the
present study did not evaluate whether or not patients
continued to receive specialist care following their initial
diagnosis.
This study excluded individuals diagnosed prior to
2009 in order to utilize precise dates of service that were
not available in the data prior to that year. Restricting
the cohort to a more recent sample may somewhat limit
the generalizability of these findings. However, for more
than 50 % of the sample, the first observed cognitive
diagnosis was for AD. In addition, for those with a first
diagnosis of cognitive impairment, the median time from
that diagnosis to AD diagnosis was less than one month.
These factors, combined with a mean duration of
follow-up similar between the two cohorts, suggest that
limiting the sample to 2009 through 2012 would not
have a substantial impact on our findings.
It is likely that AD will continue to exert a growing
and significant burden on health and social care systems.
Better understanding how best to adapt the healthcare
system to this impending epidemic may help improve
patient and system-level outcomes. Additional research
as to the most beneficial roles of specialists and primary
care providers may help expand on the current analyses
to help policy-makers reach better informed decisions
on if, how, and when to implement broader screening,
detection, and diagnostic protocols for Medicare benefi-
ciaries. Future research should consider the application
of these analyses in the broader dementia population
given the challenges of differential diagnosis. Also,
additional research is warranted to understand the impact
of continued specialist care among patients with cognitive
decline.
Conclusions
In conclusion, these analyses demonstrated that both
before and after matching, patients not diagnosed by a
specialist incurred higher costs in the year immediately
following the initial cognitive decline diagnosis. In Years
Kirson et al. BMC Geriatrics  (2016) 16:138 Page 8 of 82 and 3, costs in both cohorts remained higher than
baseline though the difference between them narrowed
and was not statistically significant at those time points.
These results suggest that seeking care from specialists
may result in more timely diagnosis and reduced costs
among those with cognitive decline.
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